New nasal nanodrops wipe out brain tumors in mice
sciencedaily - A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach the brain without invasive surgery. When paired with dru…
AI Summary: A novel nasal‐delivered nanotherapy that triggers the STING immune pathway via gold‐core nanoparticles has been shown in mice to nearly wipe out aggressive brain tumors. This noninvasive approach offers hope for a radically new treatment modality in glioblastoma.
FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation
esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study
AI Summary: The FDA has granted full approval for ziftomenib—a novel agent aimed at treating relapsed or refractory acute myeloid leukemia, especially in patients with NPM1 mutations. Backed by the KO‐MEN‐001 trial data, this decision marks a significant step forward for a patient group in dire need of new therapeutic options.
Novo Nordisk rolls out lower prices for Ozempic and Wegovy
medicalxpress - People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.
AI Summary: In a bid to ease the financial burden on self‐pay patients, Novo Nordisk has unveiled deep price cuts for its flagship GLP-1 drugs, Ozempic and Wegovy. The new pricing strategy comes amid intensifying market pressures and aims to broaden access to these critical therapies for weight management and type 2 diabetes.
Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns
Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...
AI Summary: Merck has made a blockbuster move by finalizing a $9.2 billion deal to acquire Cidara Therapeutics’ late‐stage anti‐influenza candidate. This acquisition underscores Merck’s commitment to expanding its antiviral portfolio and marks a key strategic investment in advancing flu prevention amid evolving global health threats.
F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause
Roni Caryn Rabin / nytimes - The benefits of hormone replacement have been underappreciated, Dr. Marty Makary, the agency’s commissioner, said on Monday. Critics described evidence for the change as insufficient.
AI Summary: In a bold policy pivot, the FDA will lift long‑standing black box warnings on hormone treatments for menopause. The decision – made without an official advisory committee’s input – updates labeling to better reflect current risk–benefit assessments, leaving critics to wonder if caution has finally given way to progress.
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
go - The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year
AI Summary: The FDA has revised the label for Sarepta’s Duchenne muscular dystrophy gene therapy, adding a boxed safety warning and stricter usage conditions following reports of two patient deaths. The update reflects mounting safety concerns that have prompted closer regulatory oversight.
Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation
oncodaily - Dr. Richard Pazdur, one of the most influential figures in oncology drug regulation, has been appointed Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and […]
AI Summary: The FDA has ushered in a new era in oncology drug oversight by appointing Dr. Richard Pazdur as the director of its Drug Center. The move comes amid agency challenges and staff cuts, promising stabilizing leadership at one of its most influential divisions.
FDA rolls back warning labels on HRT products for menopause, citing misinformation
fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…
AI Summary: Following a rigorous review of the scientific evidence, federal regulators are scrapping boxed warnings on hormone replacement products used for menopausal symptom relief. The move—aimed at increasing treatment access—casts a skeptical eye on long-held safety fears, inviting both applause and a few sarcastic raised eyebrows in the industry.
Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera
Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…
AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.
Pfizer poised to buy Metsera in $10 bn deal after bidding war
medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.
AI Summary: In a dramatic bidding war for a promising biotech startup, Pfizer’s improved $10 billion offer prevailed—until Novo Nordisk raised its bid yet again. This high-stakes takeover tussle underscores the fierce competition and strategic importance of emerging therapies.
#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter
Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...
AI Summary: At AHA25 in New Orleans, researchers and clinicians showcased pivotal findings – including Amgen’s cholesterol‐lowering drug cutting first‐time cardiovascular events by 25% – while experts like Avirup Guha highlighted innovative cardio‐oncology sessions. The event spotlighted the evolving intersection between heart health and cancer care.
FDA approves J&J’s Darzalex for smoldering multiple myeloma
Lei Lei Wu / endpoints - The FDA on Thursday approved Johnson & Johnson’s Darzalex injection for high-risk smoldering multiple myeloma, a condition in which people have abnormal cells that could turn into myeloma but don’t have ...
AI Summary: The FDA has approved a subcutaneous formulation of daratumumab—marketed as Darzalex—for patients with high‐risk smoldering multiple myeloma, promising a more convenient administration route. This decision is set to improve patient quality of life and streamline treatment protocols in an area of oncology where every minute counts.
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury
Ryan Cross / endpoints - A man in his early 80s who was recently hospitalized with liver injury, a few weeks after receiving an experimental gene editing therapy, died on Wednesday ...
AI Summary: A patient enrolled in an experimental CRISPR gene‐editing trial suffered severe liver injury and later died, spurring renewed scrutiny over the trial’s safety protocols. This fatality casts a long shadow on the promise of gene‐editing therapies, proving that pioneering science can come with perilous risks.
CMS unveils new Medicaid drug payment model
Max Bayer / endpoints - CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...
AI Summary: The Centers for Medicare and Medicaid Services has introduced a novel Medicaid drug payment model that employs a most-favored nation pricing strategy, aiming to rein in healthcare spending. This bold move signals a shift toward competitive pricing that, while promising cost efficiencies, also raises eyebrows over its unorthodox approach.
What Trump’s New Drug Pricing Deal Means for People With Obesity
Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
AI Summary: In a bold move to tackle the obesity crisis, the Trump administration has brokered agreements with industry giants such as Eli Lilly and Novo Nordisk to slash weight-loss drug prices. The deals, promising reductions as steep as $149 a month, have sparked both applause and debate over the future of drug pricing in America.